根據行政院衛生福利部的統計，心臟疾病已居台灣十大死因的第二位（行政院衛生福利部，2011），而心血管疾病中又以冠狀動脈心臟病（Coronary artery heart disease，簡稱CAD）占最大多數。
治療冠心症主要目的有兩個：第一，改善病患的預後，減少死亡率。第二，改善病人症狀，減少心絞痛發生，提高生活品質。一般冠狀動脈疾病臨床的標準療法均先採用藥物治療，當左主幹枝有50% 以上狹窄，主幹枝有70% 以上狹窄，或者生理參數（FFR）小於等於0.8，則需進一步積極的以心導管置入塗藥支架或冠狀動脈繞道手術治療。然兩者孰優孰劣長久以來即是醫學界爭論的焦點。過去的研究顯示，就長期死亡率或產生Q波心肌梗塞的發生率而言，兩者難分軒輊，但對於台灣人而言，經胸開刀的大手術仍存在著一定程度恐懼感，故當臨床上遇到複雜性冠狀動脈疾病患者，患者傾向於心臟內科治療（即以心導管置入塗藥支架治療）為大部分，故本文想探討影響病人選擇冠狀動脈繞道手術或以心導管置入塗藥支架治療因素分析。
本研究架構以Ajzen（1985, 1991）的計畫行為理論（Theory of Planned Behavior; TPB）為基礎，探討行為態度、主觀規範、知覺行為控制及行為意向對病人的選擇冠狀動脈繞道手術或以心導管置入塗藥支架治療的行為分析，探討這些變數是否對醫療行為有顯著影響。
本研究問卷共分五部份，分別為行為態度、主觀規範、知覺行為控制、行為意向及基本資料，經由調查200位病人，得到有效問卷199份，有效問卷回收率99.5%；運用E views計量經濟學統計軟體及LPM線性機率模型進行實證分析，建立迴歸方程式模型討論之，主要研究結論如下：(1)驗證行為態度、知覺行為控制、行為意向均有顯著關係；顯示病人對選擇心導管置入塗藥支架治療的效益有較高的健康認知，但費用昂貴又令其卻步。主要是於複雜型心血管的治療，病人對經胸開刀的大手術仍存在著一定程度恐懼感，而當個人擁有更充足的醫療認知時，會選擇冠狀動脈繞道手術，來減少再阻塞的發生。(2)驗證主觀規範並不呈現顯著關係；顯示病人面臨醫療需求時，重要關係人所期待的結果，並不會影響病人本身的決定。當病患得到充分的內外科醫生給予的風險利益評估後，會以冠狀動脈繞道作為優先考量。

According to the Ministry of Health and Welfare of the Republic of China, heart disease was ranked as the second highest leading cause of death in Taiwan (The Ministry of Health and Welfare, 2011). Most cardiovascular deaths are related to coronary artery heart diseases (CAD), heart failure caused by myocardial ischemia , arrhythmia, and poor quality of life.
The study framework was based on The Theory of Planned Behavior (TPB) developed by Icek Ajzen (1985, 1991). Behavior analysis was carried out to investigate attitude towards behavior, subjective norm, perceived behavioral control and behavior intention of patients that chose drug-eluting stents. Socio-demographic was found to have significant influence on medical behavior.

一、中文部分：
1. 中央健康保險局（2012），全民健康保險簡介（2011-2012版），http://www.nhi.gov.tw/search/search.aspx。
2. 行政院衛生福利部（2011年7月29日），100年主要死因分析，http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=11962&class_no=440&level_no=4。
3. 張孝瑛、高啟雯（2007），系統性護理指導對冠狀動脈繞道手術後出院病患健康照護需求、身體活動功能及生活品之成效探討，國防醫學院護理研究所碩士論文。
4. 郭奎妙、楊銘欽（2012），台灣診斷關聯群支付制度實施前後對醫療利用、醫療行為及醫療品質之影響─以冠狀動脈繞道手術為例，臺灣大學健康政策與管理研究所碩士論文。
5. 郭達智、蔡淑鈴、黃欽印（2009）台灣全民健保論病例計酬下心臟冠狀動脈繞道手術醫師執行數量與相關手術結果因素之探討，東海大學工業工程與經營資訊學系碩士論文。
6. 賴宜虹、邱愛富（2009，探討冠狀動脈繞道手術後病患的性生活品質及其相關因素，輔仁大學護理學系碩士論文。
7. 黃雪娥、陳科呈、殷偉賢、蔡維河、葉明陽（2010），塗藥心臟血管支架之醫療費用結構與成本效益分析-與傳統支架之比較，內科學誌，21，258- 269。
8. 鄭佳玲（2007），冠狀動脈疾病治療-塗藥支架與傳統支架之臨床結果與醫療費用分析，臺灣大學醫療機構管理研究所碩士論文。
9. 劉中平、吳學明、高憲立（2008），左主冠狀動脈疾病血管成型術之現況－藥物釋放型支架的影響，內科學誌，19:454-64。
10. 蘇美如、吳肖琪（2012），探討合併慢性腎臟病與使用塗藥支架對血管支架置入病人預後情形之影響，國立陽明大學衛生福利研究所碩士論文。
二、英文部分：
1. Ajzen, I. (1985). From intentions to actions: A theory of planned behaveor. In J. Kuhl & J.Beckman (Eds.).Action-control: From cognition to behaveor (pp.11- 39).Germany:Springer.
2. Ajzen, I. (1991). The theory of planned behavior:Organizational Behavio and Human Decision Processes, 50(2), 179-211.
3. Ajzen, I. (2002). Perceived behavioral control, self-efficacy, locus of control, and the theory of planned behavior. Journal of Applied Social Psychology, 32, 665-683.
4. Ajzen, I. (2002a) .Constructing a TPB questionnaire: Conceptual and ethodological considerations,” Retrieved December 3, 2007, from http://www-unix.oit.umass.edu/~aizen/index.html.
5. Ajzen, I & Fishbein, M. (1980). Understanding attitudes and predicting socialbehavior.Englewood Cliffs, NJ: Prentice-Hall.
6. Bhatti F, et al. (2006). The logistic EuroSCORE in cardiac surgery: how well does it predict operative risk, Heart.
7. Don Poldermans et al. (2009) Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery The Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery of the European Society of Cardiology (ESC) and endorsed by the European Society of Anaesthesiology (ESA) European Heart Journal.
8. DavidJ, et al. (2004). Cohen Cost- Effectiveness of Sirolimus- Eluting Stents for Treatment of Complex Coronary Stenoses: Results From the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) Trial11 TAXUS-IV. Circulation.
9. Frederick Feit, et al. (2000).The Bypass Angioplasty Revascularization Investigation trial, Circulation.
10. Farooq et al.( 2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet.
11. Frederick Feit, et al(2000).Long-Term Clinical Outcome in the Bypass Angioplasty Revascularization Investigation Registry Comparison With the Randomized Trial. Circulation.
12. Holmes DR Jr et al.( 2013)Venn diagrams in cardiovascular disease: the Heart Team concept. Eur Heart J.
13. Hillis LD et al.(2011) ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation.
14. King SB 3rd, et al. (2009)Angioplasty or surgery for multivessel coronary artery disease: comparison of eligible registry and randomized patients in the EAST trial and influence of treatment selection on outcomes, European Heart Journal.
15. Kaiser C, Brunner-La RHP, Buser PT(2005）, Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stents in a real-world setting: randomized Basel Stent Kosten Effektivitäts Trial (BASKET). Lancet.
16. Kappetein AP, et al. (2010) Comparison of coronary bypass surgery with drug-eluting stenting for the treatment of left main and/or three-vessel disease: 3-year follow-up of the SYNTAX trial, Eur Heart J.
17. . Lemesle G et al.(2009). Prognostic value of the Syntax score in patients undergoing coronary artery bypass grafting for three-vessel coronary artery disease. Catheter Cardiovasc Interv.
18. Nashef SA, et al. (1999) . European system for cardiac operative risk evaluation (EuroSCORE) . Eur J Cardiothorac Surg.
19. Patrick W, Serruys. (2005)Five-Year Outcomes After Coronary StentingVersus Bypass Surgery for the Treatment of Multivessel Disease: The Final Analysis of the Arterial Revascularization Therapies Study (ARTS) Randomized Trial, J Am Coll Cardiol
20. Poon M, Marx SO, Gallo R(1996), Rapamycin inhibits vascular smooth muscle cell migration. J Clin Invest.
21. Pijls NH et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME. J Am Coll Cardiol.
22. Rajiv Gulati, et al.(2009) The SYNTAX Trial: A Perspective. Circ Cardiovasc Interv.
23. Rowinsky EK & Donehower RC(1995). Paclitaxel (taxol). N Engl J Med, 332: 1004 –1014.
24. Romagnoli E, et al. (2009) EuroSCORE as predictor of in-hospital mortality after percutaneous coronary intervention, Heart.
25. Sianos G, et al. (2005).The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease, EuroIntervention.
26. Stuart J, et al. (2013)The rationale for Heart Team decision-making for patients with stable complex coronary artery disease. The heart team of cardiovascular care. Am Coll Cardiol.
27. Seiffert M et al. (2013) Severe intraprocedural complications after transcatheter aortic valve implantation: calling for a heart team approach, Eur J Cardiothorac Surg.
28. Serruys PW et al. ( 2009) Assessment of the SYNTAX score in the Syntax study. EuroIntervention.
29. Shahian DM et al.(2009) The Society of Thoracic Surgeons 2008 cardiac surgery risk models: part 1--coronary artery bypass grafting surgery. Ann Thorac Surg.